Minoryx starts a phase II/III clinical study of MIN-102 for the treatment of adrenomyeloneuropathy Blog Post

Minoryx Therapeutics –a company specialized in the development of new drugs for orphan diseases, located at the Barcelona Science Park and the TecnoCampus Mataró– announces the start of its pivotal phase II/III clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN), the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD). The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).

 

Cebiotex launches a €650,000 crowdfunding campaign to ensure that its oncological treatment reaches paediatrics Blog Post

Cebiotex—with headquarters in the Barcelona Science Park (PCB)—has launched an equity crowdfunding campaign of €650,000 through Capital Cell to ensure that its first drug, CEB-01, used in the local post-surgical treatment of soft tissue sarcomas, also reaches paediatric oncology. CEB-01 is the first therapeutic application of its innovative technology, which are based on nanofibres, for local drug delivery. In the future, however, the company aims to develop new applications for pancreatic and liver cancer, as well as glioblastoma.Since it was formed in 2012, Cebiotex has raised over €2 million from public and private funds. The success of the previous equity crowdfunding campaigns and the participation of impactful social investors has allowed Cebiotex to maintain a paediatric focus as one of the company’s strategic objectives.

 

Catalan biomedical companies attracted €153.1 million in investment in 2016 Blog Post

Catalan biomedical companies were able to attract €153.1 million in investment in 2016, a record figure for the sector. This is the main takeaway from the first Study on investment in the Biomedical industry in Catalonia 2017: Achievements and future challenges presented by CataloniaBio, based at the Barcelona Science Park, and EY at the Cercle d’Economia before some seventy members of the association, entrepreneurs, investors and other professionals. 

 

A team of UB and PCB takes part in the licence of a new technology of fluorescent dyes of biomedical interest Blog Post

A new article published in the journal Nature Protocols describes the new technology to develop a series of activable fluorophores that enable the peptide molecular labelling and improve cell-live imaging. The new study has the participation of the teams led by Rodolfo Lavilla, from the Faculty of Pharmacy and Food Sciences of the University of Barcelona and the Barcelona Science Park (PCB), and Marc Vendrell, from the Edinburgh Medical School (Scotland).    

 

AVX pharma announces initiation of a Phase 2 Clinical Trial of AVX-012 Ophthalmic Solution in Dry Eye Syndrome Blog Post

Avizorex Pharma (AVX Pharma), a clinical stage biopharmaceutical company with offices at Barcelona Science Park and focused on the development of novel therapies for Dry Eye Syndrome, today announced the initiation of a Phase 2 clinical trial, evaluating the safety and efficacy of AVX-012 Ophthalmic Solution in patients with mild-to-moderate Dry Eye Syndrome, based on the concept of modulating corneal nerve activity to stimulate basal lacrimation.

 

Researchers find a gene that causes Opitz C syndrome in the only patient diagnosed in Catalonia Blog Post

A team led by the professors Daniel Grinberg and Susana Balcells, from the Institute of Biomedicine of the University of Barcelona (IBUB) at the Barcelona Science Park has identified a gene that causes the Opitz C syndrome in the only patient in Catalonia diagnosed with this genetic disease  which, so far, does not offer treatment possibilities, prenatal diagnosis or genetic counseling. This new scientific advance is a first step to discover the genetic bases of this congenital disease, that causes severe disabilities in patients and has been diagnosed in three people in the Iberian Peninsula, and sixty people in the world.  

 

Salvador Aznar Benitah receives the VI National ‘Doctores Diz Pintado’ Cancer Research Prize Blog Post

ICREA researcher and group leader of the Stem Cells and Cancer Laboratory at IRB Barcelona, Salvador Aznar Benitah, has been awarded the VI National ‘Doctores Diz Pintado’ Cancer Research Prize. Last Saturday, he received the award during the academic session held by the University of Salamanca. The prize acknowledges Salvador Aznar Benitah’s contributions to transferring knowledge from basic to clinical research.

 

Developmental biology offers the key to finding solutions for paediatric cancer, metastasis, and regeneration Blog Post

From today and until Wednesday,  around 20 speakers from around the world and 150 participants will debate cutting-edge research into plasticity and cell migration—two key aspects in paediatric cancer, metastasis, and regeneration, at the Institut d’Estudis Catalans on the occasion of the 18th Barcelona Biomed Conference, an event organised by the Institute for Research in Biomedicine (IRB Barcelona) –based at PCB– with the support of the BBVA Foundation.

 

Using 3D printing to produce crucial biomedical research tools Blog Post

IBEC Director Josep Samitier and the Technology Transfer unit introduced IBEC’s 3D bioprinting capabilities at the first IN(3D)USTRY: From Needs to Solutions event, which was held at Fira Barcelona last week. IBEC’s 3D bioprinter is the only one offering the level of precision and characteristics requred for regenerative medicine purposes in southern Europe, and one of very few on the continent. It promises to put IBEC –based at Barcelona Science Park (PCB)– at the forefront of a new revolution in regenerative medicine by allowing researchers to add biological properties to implanted tissues such as bone, and may eventually be able to manufacture entire organs for transplantation.

 

The fair “Live Research” takes off at CosmoCaixa Blog Post

Bringing science to society, fostering communication between the public and researchers and promote scientific vocation among the young are the aims of the Live Research fair, that started yesterday at CosmoCaixa Barcelona until Saturday 9th April. The exhibit has been organized by the Barcelona Science Park (PCB) and Obra Social ”la Caixa” with the support of the Barcelona City Council and the collaboration of the University of Barcelona (UB).